Prognostic factors of survival and comparison of surgically resected combined hepatocellular-cholangiocellular carcinoma, hepatocellular carcinoma, and intrahepatic cholangiocarcinoma

IRCMJ logo
PDF

Keywords

Combined hepatocellular and cholangiocellular carcinoma
Cholangiocarcinoma
Hepatocellular carcinoma
Primary liver tumors
Survival factors

How to Cite

DuzkoyluY., UstunerM. A., TurhanN., & BostanciE. B. (2021). Prognostic factors of survival and comparison of surgically resected combined hepatocellular-cholangiocellular carcinoma, hepatocellular carcinoma, and intrahepatic cholangiocarcinoma . Iranian Red Crescent Medical Journal, 23(4). https://doi.org/10.32592/ircmj.2021.23.4.225

Abstract

BackgroundHepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) are the most common primary malignancies of the liver. The combined form of these two tumors (i.e., cHC-CC) is a considerably rare type of liver cancer displaying both malignant components.

Methods: In this research, 53 patients were evaluated retrospectively, who had undergone an operation for primary liver tumors in a single tertiary center, in terms of demographics, operation, tumor features, histopathological analysis, and their relationship with survival.

Results: The study groups consisted of 20 ( 37.7%) and 33 (62.3%) females and males, respectively, with a mean age of 62.3 years. It was revealed that the survival rate was significantly higher in HCC, compared to other groups (P<0.05). Moreover, alpha-fetoprotein (AFP) was significantly higher in the HCC group than in the ICC group, and carbohydrate antigen 19-9 levels and the presence of jaundice and perineural invasion were significantly higher in the ICC group, compared to HCC patients. In the HCC group, macroscopic vascular invasion, perineural invasion, and T staging were statistically significant. It was also found that in the ICC group, the macroscopic vascular invasion was statistically significant, and in the cHC-ICC group, the increased levels of AFP showed a statistically significant effect on survival (P<0.05).

Conclusions: To the best of our knowledge, the current research was one of the very few studies performed focusing on each group of liver tumors in a single study. Based on the findings of this research, there were statistically significant results in all three groups and their comparison with each other.

 

https://doi.org/10.32592/ircmj.2021.23.4.225
PDF

References

  1. Wu SD, Ma YS, Fang Y, Liu LL, Fu D,Shen XZ. Role of the microenvironment in hepatocellular carcinoma development and progression. Cancer Treat Rev. 2012;38(3):218‑25. doi: 10.1016/j.ctrv.2011.06.010. [PubMed: 21763074].
  2. Ryerson AB, Eheman CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, et al. Annual Report to the nation on the status of cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer. 2016;122(9):1312-37. doi: 10.1002/cncr.29936. [PubMed: 26959385].
  3. Li J, Hansen BE, Peppelenbosch MP, De Man RA, Pan Q, Prengers D. Factors associated with ethnical disparity in overall survival for patients with hepatocellular carcinoma. Oncotarget. 2017;8(9):15193-204. doi: 10.18632/oncotarget.14771. [PubMed: 28122352].
  4. Patel SS, Nelson R, Sanchez J, Lee W, Uyeno L, Garcia-Aguilar J, et al. Elderly patients with colon cancer have unique tumor characteristics and poor survival. Cancer. 2013;119(4):739-47. doi: 10.1002/cncr.27753. [PubMed: 23011893].
  5. Keswani RN, Ahmed A, Keeffe EB. Older age and liver transplantation: a review. Liver Transpl. 2004;10(8):957-67. doi: 10.1002/lt.20155. [PubMed: 15390320].
  6. Khan SA, Taylor-Robinson SD, ToledanoMB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002;37(6):806-13. doi: 10.1016/s0168-8278(02)00297-0. [PubMed: 12445422].
  7. Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012;61(12):1657-69. doi: 10.1136/gutjnl-2011-301748. [PubMed: 22895392].
  8. Altekruse SF, Petrick JL, Rolin AI, Cuccinelli JE, Zou Z, Tatalovich Z, et al. Geographic variation of intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and hepatocellular carcinoma in the United States. PLoS One. 2015;10(3):e0120574. doi: 10.1371/journal.pone.0120574. [PubMed: 25837669].
  9. Zhang Y, Shi SM, Yang H, Yang LX, Wang Z, Li XD, et al. Systemic inflammation score predicts survival in patients with intrahepatic cholangiocarcinoma undergoing curative resection. J Cancer. 2019;10(2):494-503. doi: 10.7150/jca.26890. [PubMed: 30719145].
  10. Aishima S, Kuroda Y, Asayama Y, Taguchi K, Nishihara Y, Taketomi A, et al. Prognostic impact of cholangiocellular and sarcomatous components in combined hepatocellular and cholangiocarcinoma. Hum Pathol. 2006;37(3):283-91. doi: 10.1016/j.humpath.2005.08.019. [PubMed: 16613323].
  11. Allen RA, Lisa JR. Combined liver cell and bile duct carcinoma. Am J Pathol. 1949;25(4):647-55. [PubMed: 18152860].
  12. The Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. Jpn J Surg. 1989;19(1):98-129. doi: 10.1007/BF02471576. [PubMed: 2659865].
  13. Tang D, Nagano H, Nakamura M, Wada H, Marubashi S, Miyamoto A, et al. Clinical and pathological features of Allen's type C classification of resected combined hepatocellular and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma. J Gastrointest Surg. 2006;10(7):987-98. doi: 10.1016/j.gassur.2006.01.018. [PubMed: 16843869].
  14. Nishi H, Taguchi K, Asayama Y, Aishima S, Sugimachi K, Nawata H, et al. Sarcomatous hepatocellular carcinoma: a special reference to ordinary hepatocellular carcinoma. J Gastroenterol Hepatol. 2003;18(4):415-23. doi: 10.1046/j.1440-1746.2003.02888.x. [PubMed: 12653890].
  15. Ramanathan M, Shroads M, Choi M, Wood D, Seetharam A. Predictors of intermediate-term survival with destination locoregional therapy of hepatocellular cancer in patients either ineligible or unwilling for liver transplantation. J Gastrointest Oncol. 2017;8(5):885-9. doi: 10.21037/jgo.2017.07.05. [PubMed: 29184693].
  16. Dhir M, Lyden ER, Smith LM. Are C. Comparison of outcomes of transplantation and resection in patients with early hepatocellular carcinoma: a meta-analysis. HPB (Oxford). 2012;14(9):635-45. doi: 10.1111/j.1477-2574.2012.00500.x. [PubMed: 22882201].
  17. Kim J, Ko ME, Nelson RA, Arrington A, Luu C, Falor AE, et al. Increasing age and survival after orthotopic liver transplantation for patients with hepatocellular cancer. J Am Coll Surg. 2014;218(3):431-8. doi: 10.1016/j.jamcollsurg.2013.12.001. [PubMed: 24559955].
  18. Bibani N, Trad D, Sabbah M, Ouakaa A, Elloumi H, Gargouri D, et al. Prognostic factors of survival during hepatocellular carcinoma. La Tunisie Med. 2018;96(6):379-84. [PubMed: 30430477].
  19. Bauschke A, Altendorf-Hofmann A, Malessa C, Schüle S, Zanow J, Settmacher U. Which factors affect the long-term survival of patients with hepatocellular carcinoma UICC stage IV? J Cancer Res Clin Oncol. 2016;142(12):2593-601. doi: 10.1007/s00432-016-2260-y. [PubMed: 27630023].
  20. Altman AM, Kizy S, Marmor S, Huang JL, Denbo JW, Jensen EH. Current survival and treatment trends for surgically resected intrahepatic cholangiocarcinoma in the United States. J Gastrointest Oncol. 2018;9(5):942-52. doi: 10.21037/jgo.2017.11.06. [PubMed: 30505597].
  21. Ribero D, Pinna AD, Guglielmi A, Ponti A, Nuzzo G, Giulini SM, et al. Surgical approach for long-term survival of patients with ıntrahepatic cholangiocarcinoma: a multi-institutional analysis of 434 patients. Arch Surg. 2012;147(12):1107-13. doi: 10.1001/archsurg.2012.1962. [PubMed: 22910846].
  22. Borie F, Niampa H, Bouvier AM, Faivre J, Launoy G, Delafosse P, et al. Current management and prognosis of intrahepatic cholangiocarcinoma in France. Gastroenterol Clin Biol. 2009;33(10-11):971-6. doi: 10.1016/j.gcb.2009.05.012. [PubMed: 19647386].
  23. Sotiropoulos GC, Miyazaki M, Konstadoulakis MM, Paul A, Molmenti EP, Gomatos IP, et al. Multicentric evaluation of a clinical and prognostic scoring system predictive of survival after resection of intrahepatic cholangiocarcinomas. Liver Int. 2010;30(7):996-1002. doi: 10.1111/j.1478-3231.2010.02203.x. [PubMed: 20141593].
  24. Uhlig J, Sellers CM, Cha C, Khan SA, Lacy J, Stein SM, et al. Intrahepatic cholangiocarcinoma: socioeconomic discrepancies, contemporary treatment approaches and survival trends from the national cancer database. Ann Surg Oncol. 2019;26(7):1993-2000. doi: 10.1245/s10434-019-07175-4. [PubMed: 30693451].
  25. Yano Y, Yamamoto J, Kosuge T, Sakamoto Y, Yamasaki S, Shimada K, et al. Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases. Jpn J Clin Oncol. 2003;33(6):283-7. doi: 10.1093/jjco/hyg056. [PubMed: 12913082].
  26. Ng IO, Shek TW, Nicholls J, Ma LT. Combined hepatocellular cholangiocarcinoma: a clinicopathological study. J Gastroentenol Hepatol. 1998;13(1):34-40. doi: 10.1111/j.1440-1746.1998.tb00542.x. [PubMed: 9737569].
  27. Sell S, Dunsford HA. Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma. Am J Pathol. 1989;134(6):1347-63. [PubMed: 2474256].
  28. Wells HG. Primarycarcinoma of theliver. Am J Med Sci. 1903;126(3):403-17.
  29. Maeda T, Adachi E, Kajiyama K, Sugimachi K, Tsuneyoshi M. Combined hepatocellular and cholangiocarcinoma: Proposed criteria according to cytokeratin expression and analysis of clinicopathologic features. Hum Pathol. 1995;26(9):956-64. doi: 10.1016/0046-8177(95)90084-5. [PubMed: 7545644].
  30. Uenishi T, Hirohashi K, Shuto T, Yamamoto T, Kubo S, Tanaka H, et al. Surgery for mixed hepatocellular and cholangiocellularcarcinoma. Hepatogastroenterology. 2000;47(33):832-4. [PubMed: 10919041].